India, Aug. 28 -- Heartflow, Inc. (HTFL), an AI technology company focused on diagnosing and managing coronary artery disease (CAD), announced one-year results from the independent, government-funded FUSION trial.
The study showed that Heartflow FFRCT Analysis reduced unnecessary invasive coronary angiography (ICA) procedures by 44% compared with standard coronary computed tomography angiography (CCTA) alone.
The late-breaking results were presented at the European Society of Cardiology (ESC) Congress 2026 and published simultaneously in the Journal of the American College of Cardiology (JACC).
The FUSION trial enrolled 528 patients with stable chest pain across 12 hospitals in the Netherlands and evaluated Heartflow FFRCT Analysis follo...